ISB 1442 Trial for Relapsed Multiple Myeloma Terminated Early
A first-in-human Phase 1/2 trial of ISB 1442 in relapsed/refractory multiple myeloma was halted before completion.
Summary
ISB 1442 is an experimental bispecific antibody developed by Ichnos Sciences that was being tested in patients with relapsed or refractory multiple myeloma — a blood cancer that returns after or fails to respond to prior treatment. This first-in-human study was designed to evaluate both safety and early efficacy, starting with escalating subcutaneous doses and then moving to a recommended Phase 2 dose. The trial enrolled patients across Phase 1 and Phase 2 stages but was ultimately terminated before completion. The reasons for termination have not been publicly disclosed in the available abstract. While the early-phase structure was methodologically sound, the premature end of the study limits any conclusions about ISB 1442's benefit or safety profile for this difficult-to-treat cancer population.
Detailed Summary
Multiple myeloma is a cancer of plasma cells in the bone marrow, and relapsed or refractory cases — those that return after treatment or stop responding — represent one of oncology's most challenging scenarios. Novel immunotherapies, particularly bispecific antibodies that redirect the immune system against cancer cells, have emerged as a promising frontier. ISB 1442 was one such experimental agent entering human testing for the first time in this trial.
The study was a first-in-human, open-label, Phase 1/2 trial sponsored by Ichnos Sciences SA. It was designed to evaluate ISB 1442 administered as a subcutaneous injection in escalating doses during Phase 1 to establish safety and tolerability, followed by a Phase 2 expansion at the recommended dose to assess efficacy in relapsed/refractory multiple myeloma patients.
Unfortunately, the trial was terminated before it could generate comprehensive results. The ClinicalTrials.gov registration lists the study status as terminated, though no detailed explanation for the decision is available in the public abstract. Termination of early-phase oncology trials can occur for multiple reasons, including safety signals, strategic business decisions, insufficient enrollment, or emerging competitive data.
The practical implications for clinicians and patients are limited at this stage. Without published safety or efficacy data, it is impossible to assess whether ISB 1442 showed any promise or encountered concerning adverse events. The bispecific antibody class remains highly active in myeloma research, with several other agents advancing in trials.
This termination underscores the high attrition rate in early oncology drug development. For the myeloma community, the focus will likely remain on approved bispecifics and CAR-T therapies while next-generation candidates continue through development pipelines.
Key Findings
- ISB 1442, a bispecific antibody for multiple myeloma, entered first-in-human Phase 1/2 testing via subcutaneous injection.
- The trial was terminated before completion; reasons for termination are not publicly disclosed.
- No efficacy or safety outcome data are available from this study in public records.
- The bispecific antibody class remains an active area of myeloma research despite this setback.
Methodology
This was a first-in-human, open-label, Phase 1/2 dose-escalation study using subcutaneous ISB 1442 in patients with relapsed/refractory multiple myeloma. Phase 1 involved escalating doses to establish safety; Phase 2 would have used the recommended Phase 2 dose. The study was registered in September 2022 and subsequently terminated.
Study Limitations
This summary is based on the abstract and ClinicalTrials.gov registration only — full trial data, patient outcomes, and the reasons for termination are not publicly available. The lack of results data makes it impossible to assess the drug's safety or efficacy. No conclusions about ISB 1442's clinical potential can be drawn from this record alone.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.